|
Metabolic Syndrome X
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Four genetic variants (APOA5_rs651821, EFCAB4B_rs4766165, ZNF259_rs2160669 and APOBEC1_rs10845640) were selected because they increased MetS risk after adjusting for covariates.
|
31544728 |
2019 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Wild-type mice, atherosclerotic mice with double knockout (DKO) of the low-density lipoprotein receptor and Apobec-1, and DKO mice treated with the Nox-inhibitor apocynin were studied at baseline and at 3 and 21 days after closed-chest MI.
|
30139430 |
2018 |
|
Anaplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Apobec1 Promotes Neurotoxicity-Induced Dedifferentiation of Müller Glial Cells.
|
28150227 |
2017 |
|
Epilepsy, Temporal Lobe
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Together, these results demonstrate Apobec-1-dependent expression of RNA-edited GlyR protein in neurons and identify the <i>APOBEC1</i> 80I/M-coding alleles as new genetic risk factors for iTLE patients.
|
29375302 |
2017 |
|
Complex partial seizures
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Patients with expression of the Apobec-1 80I variant mostly suffered from simple or complex partial seizures, whereas patients with 80M expression exhibited secondarily generalized seizure activity.
|
29375302 |
2017 |
|
Familial hypercholesterolemia - heterozygous
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, we expressed hIDOL in a 'humanized' mouse model of heterozygous familial hypercholesterolaemia (LDLR(+/-)/Apobec1(-/-)/hApoB-Tg, LAhB).
|
26786161 |
2016 |
|
Testicular Germ Cell Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we show that partial loss of either APOBEC1 complementation factor (A1CF), the RNA-binding cofactor of APOBEC1 in RNA editing, or Argonaute 2 (AGO2), a key factor in the biogenesis of certain noncoding RNAs, modulates risk for TGCTs and testicular abnormalities in both parent-of-origin and conventional genetic manners.
|
27582469 |
2016 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Such APOBEC1-induced mutator phenotypes could play a role in the onset of esophageal adenocarcinomas.
|
25085003 |
2014 |
|
Barrett Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Cerebral Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Apobec-1 could upregulate COX-2 expression in neurogenic cells by stabilizing COX-2 mRNA, and might aggravate injury of oxygen-glucose deprivation in neurogenic cells as well as in rats with cerebral ischemia.
|
23609497 |
2013 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Then the correlation of Apobec-1 level and injury severity was analyzed in cells with oxygen-glucose deprivation and in rats with middle cerebral artery occlusion.
|
23609497 |
2013 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Murine APOBEC1 was able to hyperdeaminate cytidine residues in murine leukemia virus genomic RNA as well.
|
18983852 |
2009 |
|
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Murine APOBEC1 was able to hyperdeaminate cytidine residues in murine leukemia virus genomic RNA as well.
|
18983852 |
2009 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In addition, there was reduced expression in adenomas from compound Apc(min/+) apobec-1(-/-) mice of other mRNAs (including epidermal growth factor receptor, peroxisome proliferator-activated receptor delta, prostaglandin receptor EP4, and c-myc), each containing the apobec-1 consensus binding site within their 3'-UTR.
|
17875695 |
2007 |
|
Cholelithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate APOBEC1 and PPARG as candidate genes for common symptomatic gallstone disease in humans.
|
17696929 |
2007 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated apobec-1 introduction into HCA-7 (colorectal cancer) cells showed a dose-dependent increase in Cox-2 protein and stabilization of endogenous Cox-2 mRNA.
|
17875695 |
2007 |
|
Intestinal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice.
|
17875695 |
2007 |
|
Cholecystolithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the investigated German samples, no evidence of association of APOBEC1 and PPARG with gallstone susceptibility was detected.
|
17696929 |
2007 |
|
Intestinal adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that deletion of apobec-1, by modulating expression of AU-rich RNA targets, provides an important mechanism for attenuating a dominant genetic restriction point in intestinal adenoma formation.
|
17875695 |
2007 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Members of the APOBEC (apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1-like) family of cytidine deaminases inhibit host cell genome invasion by exogenous retroviruses and endogenous retrotransposons.
|
17166910 |
2007 |
|
Adenoma of small intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we show that small intestinal adenoma formation is dramatically reduced in compound Apc(min/+) apobec-1(-/-) mice when compared with the parental Apc(min/+) strain.
|
17875695 |
2007 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated apobec-1 introduction into HCA-7 (colorectal cancer) cells showed a dose-dependent increase in Cox-2 protein and stabilization of endogenous Cox-2 mRNA.
|
17875695 |
2007 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.
|
10597235 |
1999 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The 'auxiliary' components of the apo B mRNA editing enzyme-complex are missing in many tumors including colorectal and gastric carcinoma, but are highly expressed in hepatocellular, lung adeno- and breast carcinoma all of which lack APOBEC-1.
|
10597235 |
1999 |